ES2172589T3 - Tratamiento de la apoplegia asociada con la infiltracion de macrofagos. - Google Patents

Tratamiento de la apoplegia asociada con la infiltracion de macrofagos.

Info

Publication number
ES2172589T3
ES2172589T3 ES95926813T ES95926813T ES2172589T3 ES 2172589 T3 ES2172589 T3 ES 2172589T3 ES 95926813 T ES95926813 T ES 95926813T ES 95926813 T ES95926813 T ES 95926813T ES 2172589 T3 ES2172589 T3 ES 2172589T3
Authority
ES
Spain
Prior art keywords
infiltration
treatment
macrofagos
apoplegia
affection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95926813T
Other languages
English (en)
Inventor
Eva Anne Turley
Samuel Simon Asculai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Jagotec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec AG filed Critical Jagotec AG
Application granted granted Critical
Publication of ES2172589T3 publication Critical patent/ES2172589T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE ACIDO HIALURONICO Y/O SALES DE ESTE PARA EL TRATAMIENTO DE UN SER HUMANO QUE TIENE UNA ENFERMEDAD O AFECCION CARACTERIZADA POR LA INFILTRACION DE MACROFAGOS, NEUTROFILOS U OTROS GLOBULOS BLANCOS DENTRO DE UN AREA DAÑADA POR ESA ENFERMEDAD O AFECCION, IMPLICANDO DICHO USO LA UTILIZACION DE UNA CANTIDAD EFECTIVA DE ACIDO HIALURONICO Y/O SALES DE ESTE DURANTE EL PERIODO DE TIEMPO QUE SE NECESITE.
ES95926813T 1994-08-24 1995-08-02 Tratamiento de la apoplegia asociada con la infiltracion de macrofagos. Expired - Lifetime ES2172589T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002130762A CA2130762C (en) 1994-08-24 1994-08-24 Treatment of disease and conditions associated with macrophage infiltration

Publications (1)

Publication Number Publication Date
ES2172589T3 true ES2172589T3 (es) 2002-10-01

Family

ID=4154227

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95926813T Expired - Lifetime ES2172589T3 (es) 1994-08-24 1995-08-02 Tratamiento de la apoplegia asociada con la infiltracion de macrofagos.

Country Status (14)

Country Link
EP (1) EP0777487B1 (es)
JP (1) JP4111537B2 (es)
KR (1) KR970705402A (es)
CN (1) CN1131539A (es)
AP (1) AP619A (es)
AT (1) ATE212850T1 (es)
AU (1) AU701014B2 (es)
CA (1) CA2130762C (es)
DE (1) DE69525349T2 (es)
ES (1) ES2172589T3 (es)
HU (1) HUT76895A (es)
IL (1) IL114915A0 (es)
WO (1) WO1996005845A2 (es)
ZA (1) ZA957056B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
DE69723702T2 (de) * 1996-03-14 2004-06-03 The Governors Of The University Of Alberta, Edmonton Verwendung von hyaluronsäure zur zellmobilisierung
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
AU2745700A (en) 1999-02-01 2000-08-18 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
EP1162984A2 (en) * 1999-03-15 2001-12-19 Trustees Of Boston University Use of cross linked polysaccharides for the inhibition of angiogenesis
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
US20210069297A1 (en) * 2017-09-01 2021-03-11 Excel Med, Llc Viscous composition for treating ischemia
KR20200083974A (ko) * 2017-09-05 2020-07-09 엑셀 메드, 엘엘씨 허혈 치료용 헤파린 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2498524B1 (fr) * 1981-01-27 1986-07-25 Thomson Csf Dispositif electromecanique d'impression pour imprimante du type serie-parallele et telecopieur comportant un tel dispositif
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US4725585A (en) * 1985-04-26 1988-02-16 Pharmacia Ab Method of enhancing the host defense
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
WO1993016737A1 (en) * 1992-02-24 1993-09-02 Simmons Paul L Biodegradable germicide

Also Published As

Publication number Publication date
WO1996005845A2 (en) 1996-02-29
AP9500757A0 (en) 1995-10-31
EP0777487B1 (en) 2002-02-06
KR970705402A (ko) 1997-10-09
DE69525349T2 (de) 2002-10-31
ZA957056B (en) 1996-03-26
IL114915A0 (en) 1995-12-08
AU3107095A (en) 1996-03-14
JPH10506884A (ja) 1998-07-07
AP619A (en) 1997-10-10
CA2130762A1 (en) 1996-02-25
AU701014B2 (en) 1999-01-21
HUT76895A (en) 1997-12-29
WO1996005845A3 (en) 1996-04-11
JP4111537B2 (ja) 2008-07-02
CA2130762C (en) 1999-07-06
EP0777487A1 (en) 1997-06-11
DE69525349D1 (de) 2002-03-21
CN1131539A (zh) 1996-09-25
ATE212850T1 (de) 2002-02-15

Similar Documents

Publication Publication Date Title
ATE241402T1 (de) R-x sicherheitskatheter
FI922735A7 (fi) Uudet säiliöjärjestelmät ja vesipitoiset koostumukset
ES2133130B1 (es) Nueva formulacion de budesonida, su uso y recipiente que la contiene.
ES2031806T3 (es) Factor de permeabilidad vascular humano.
DE69533549D1 (de) Implantierbare pumpe zur verabreichung einer arznei
TR26837A (tr) Isitarak dumanli dezenfeksiyon sureti ile hasaratin öldürülmesine mahsus usul
DE3584274D1 (de) Knochenreparatur mit hilfe von kollagen.
MX157579A (es) Mejoras a dispositivo quirurgico para ser insertado en el cuerpo humano,que tiene una sonda larga
ES2037818T3 (es) Utilizacion de un derivado del acido 3-hidroxibutanoico.
ES2093774T3 (es) Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
FI931336A0 (fi) Laekemedel som innehaoller polyhydroximetylenderivat, foerfarande foer deras framstaellning och bruk
DE68917189D1 (de) Fluor enthaltendes Phosphatester, dessen Herstellung und dieses enthaltendes Rostschutzmittel.
ES2133412T3 (es) 2',5'-oligoadenilato-2',3'-ciclofosfatos y 2',5'-oligoadenilatos con actividad sobre el virus papiloma.
ES2032888T3 (es) Productos conservados para la limpieza del cabello y el cuerpo y utilizacion de una combinacion de sustancias conservantes.
DE3688946D1 (de) Röntgenstrahlungsquelle.
DE68915503D1 (de) Zahnchirurgisches Gerät, geeignet für die Versorgung von gekoppelten Handstücken mit drei unterschiedlichen Fluida.
ES2191211T3 (es) Uso de acido peracetico en piscicultura.
ES2086538T3 (es) Medicamento para el tratamiento de la hiperlipemia y/o aterosclerosis.
NO913798D0 (no) Fremgangsmaate for fremming av utfelling av kalsiumkarbonatavsetning i vandige systemer.
ES2128794T3 (es) Composiciones de poliuretano con reactividad estable.
ES492195A0 (es) Clavo elastico para la reduccion de fractura de trocanter e implantacion que utiliza este clavo elastico
FI881862A7 (fi) Ortopedinen sidos.
FI821324A0 (fi) Oxazolderivat
ES2043238T3 (es) Agente y proceso para la limpieza de sistemas de irrigacion o distribucion de agua usados en por ejemplo agricultura y horticultura.
ES2076518T3 (es) Preparacion dermatologica.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 777487

Country of ref document: ES